MSA
CADX

Mason Street Advisors’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Mason Street Advisors’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-249,600
Closed -$2.26M – 1902
2013
Q4 		$2.26M Hold
249,600
– – 0.02% 880
2013
Q3 		$1.57M Buy
+249,600
New +$1.59M 0.02% 802

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Mason Street Advisors's CADX Position: Q1 2014 in Review

Mason Street Advisors sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 249,600 shares — an estimated $2.26M sold.

Mason Street Advisors first reported a position in CADX in Q3 2013 and held it in 2 quarters. The position peaked at $2.26M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Mason Street Advisors reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Mason Street Advisors sold 249,600 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $2.26M.
  • Mason Street Advisors first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q3 2013 and held it in 2 quarters.
  • Mason Street Advisors's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $2.26M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Mason Street Advisors's 13F filing for Q1 2014, filed 15 May 2014.